Search clinical trials for: IDH

Total 230 results

Hutchmed

Not yet recruiting

A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia
Huashan Hospital

Not yet recruiting

Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma

Glioma | Glioblastoma

China
Shuttle Pharmaceuticals, Inc.

Not yet recruiting

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Glioblastoma, IDH-wildtype

United States
Neonc Technologies, Inc.

Not yet recruiting

A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

High Grade Glioma | Pineocytoma | Diffuse Midline Glioma, H3 K27M-Mutant | Spinal Cord Tumor | Pediatric Tumor of CNS | Pediatric Tumor of Brain | Pediatric Tumor of Brain Stem | Choroid Plexus Carcinoma, Childhood
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-Wildtype
Tianjin Medical University General Hospital

Recruiting

Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma

Glioblastoma, IDH-wildtype

China
ECOG-ACRIN Cancer Research Group

Not yet recruiting

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

Glioblastoma, IDH-Wildtype
University of Chicago

Not yet recruiting

Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation (MPN)

Myeloproliferative Neoplasms

United States
Jasper Gerritsen
Massachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaborators

Recruiting

The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) (RECSUR)

Glioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, Malignant

United States, Germany, Netherlands, Switzerland, Belgium
Erasmus Medical Center
Massachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaborators

Recruiting

The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma (RECMAP)

Glioblastoma | Brain Neoplasms | Recurrent Glioblastoma | Recurrent Adult Brain Tumor | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme of Brain | Brain Neoplasms, Adult, Malignant | Astrocytoma, Malignant | Brain Neoplasms, Adult

United States, Germany, Switzerland, Belgium, Netherlands
Washington University School of Medicine
Bristol-Myers Squibb; Damon Runyon Cancer Research Foundation

Not yet recruiting

Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial

Clonal Cytopenia of Undetermined Significance | CCUS Clonal Cytopenia of Undetermined Significance

United States
Assiut University

Not yet recruiting

IDH1 and OCT4 in High Grade Astrocytoma

High Grade Astrocytoma
iOMEDICO AG

Recruiting

Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC (CONFIDHENCE)

Acute Myeloid Leukemia (AML)

Germany
Erasmus Medical Center
Universitaire Ziekenhuizen KU Leuven; University Medical Center Groningen; Academisch... and other collaborators

Not yet recruiting

Short Term Outcomes After PRoton And photoN radiOtherapy for IDH Mutated Grade 2 and 3 Gliomas (SOPRANO)

Glioma | Radiotherapy; Complications
National Cancer Institute (NCI)

Recruiting

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

Locally Advanced Chondrosarcoma | Metastatic Chondrosarcoma | Metastatic Sinonasal Adenocarcinoma | Locally Advanced Sinonasal Adenocarcinoma | Metastatic Large-cell Neuroendocrine Carcinoma | Locally Advanced Large-cell Neuroendocrine Carcinoma | Metastatic Olfactory Neuroblastoma | Locally Advanced... and other conditions

United States
Rigel Pharmaceuticals
Nationwide Children's Hospital

Not yet recruiting

Study of Olutasidenib and Temozolomide in HGG

Astrocytoma | High Grade Glioma | Oligodendroglioma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | Spinal Tumor | Astrocytoma, Grade III | Astrocytoma, Grade IV | IDH1 Mutation | WHO Grade IV Glioma | Thalamus Tumor | IDH1 R132 | IDH1 R132C | IDH1 R132H and other conditions

United States, Australia, United Kingdom, Canada, Germany, Netherlands
Cure 51
Centre Leon Berard; Charite University, Berlin, Germany; Gustave Roussy, Cancer... and other collaborators

Recruiting

Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis (ROSALIND)

Pancreas Adenocarcinoma | Small-cell Lung Cancer | Glioblastoma, IDH-wildtype

France
Jasper Gerritsen
Massachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaborators

Recruiting

The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202) (RESBIOP)

Glioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain

United States, Belgium, Switzerland, Germany, Netherlands
Jasper Gerritsen
Massachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaborators

Recruiting

The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203) (PALSUR)

Glioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult

United States, Belgium, Switzerland, Germany, Netherlands
Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier

Not yet recruiting

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen (CHONQUER)

Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Jasper Gerritsen
Massachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaborators

Recruiting

The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201) (SUPRAMAX)

Glioblastoma | Brain Neoplasms | Astrocytoma, Grade III | High-grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Brain Neoplasm, Primary | Brain Neoplasm, Malignant | Astrocytoma, Malignant | Brain Neoplasms, Adult

United States, Germany, Belgium, Switzerland, Netherlands
Istituto Oncologico Veneto IRCCS
Bayer S.p.A

Recruiting

Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients (REGOMA-2)

Glioblastoma, IDH-wildtype | MGMT-Methylated Glioblastoma

Italy
Neonc Technologies, Inc.

Recruiting

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Gastroesophageal Junction... and other conditions

United States
Erasmus Medical Center

Recruiting

Physiological MRI for Precision Radiotherapy IDH-wildtype Glioblastoma (PhysMRRT)

Glioblastoma

Netherlands
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

DESTINY Breast Respond HER2-low Europe

Metastatic Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast Cancer

Austria, Belgium, Italy, Spain, France, Switzerland, Denmark, Norway, Sweden
Fondazione Policlinico Universitario Agostino Gemelli...
Oslo University Hospital; Istituto Superiore di Sanità; University Medical Center... and other collaborators

Not yet recruiting

Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma (IPerGlioGEM)

Glioblastoma, IDH-wildtype

Italy
University of Milano Bicocca

Not yet recruiting

Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma

Malignancies | Glioblastoma, IDH-wildtype | Metformin

Italy
Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier

Recruiting

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

IDH1-mutant Cholangiocarcinoma

United States, United Kingdom
Servier Affaires Médicales

Recruiting

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Acute Myeloid Leukemia (AML)

Netherlands, Italy, Austria, France
Asan Medical Center
Korean Cancer Study Group; Boryung Pharmaceutical Co., Ltd

Recruiting

A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer (BRISK)

Advanced Solid Tumors | Metastatic Cancer | Solid Tumors

Korea, Republic of
Northwestern University
National Cancer Institute (NCI); Moleculin Biotech, Inc.

Not yet recruiting

WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-Wildtype

United States
Orbus Therapeutics, Inc.

Recruiting

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Glioblastoma | Glioblastoma Multiforme | GBM | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

United States
Northwestern University
Agenus Inc.; CarThera

Recruiting

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Glioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype

United States
National Cancer Institute (NCI)

Recruiting

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

Recurrent WHO Grade 2 Glioma | Recurrent Glioblastoma, IDH-Wildtype | Recurrent WHO Grade 3 Glioma

United States
Robert Bok, MD, PhD
National Cancer Institute (NCI)

Recruiting

Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma

Adult Gliomas, Mixed

United States
Peking Union Medical College Hospital

Not yet recruiting

Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma

Glioblastoma, IDH-wildtype

China
AnHeart Therapeutics Inc.

Recruiting

IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor

Cholangiocarcinoma With IDH1 Mutation | Solid Tumors With IDH1 Mutation

China
Debiopharm International SA

Recruiting

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Astrocytoma, Grade III | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Spain, United States, Switzerland
Memorial Sloan Kettering Cancer Center
Astellas Pharma US, Inc.

Recruiting

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

United States
University of Zurich
Swiss National Science Foundation

Recruiting

Glutamate Inhibitors in Glioblastoma (GLUGLIO)

Glioblastoma

Switzerland
Katy Peters, MD, PhD
Servier

Not yet recruiting

ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas (ViCToRy)

Low Grade Glioma of Brain

United States
Assiut University

Not yet recruiting

Correlation Between SPECT/CT and IDH Mutation in Brain Glioma

Brain Glioma
Assiut University

Not yet recruiting

Single Photon Emission Computed Tomography/Computed Tomography With Pentavalent 99mTc Dimercaptosuccinic Acid in Patients With Brain Glioma; Correlation With IDH Mutation

Brain Glioma
National Cancer Institute (NCI)

Recruiting

Study of Zotiraciclib for Recurrent High-Grade Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Cancer | Brain Tumor

United States
Sunnybrook Health Sciences Centre

Recruiting

UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly (UNITED2)

Glioblastoma, IDH-mutant | Glioblastoma Multiforme, Adult

Canada
Institut de Recherches Internationales Servier
Merck Sharp & Dohme LLC

Recruiting

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Glioma

Astrocytoma

United States
Mayo Clinic
Merck Sharp & Dohme LLC; NeoImmune Tech

Recruiting

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-Wildtype | Recurrent Gliosarcoma | High Grade Astrocytic Tumor

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Massachusetts General Hospital
GlaxoSmithKline

Recruiting

Niraparib In Recurrent IDH 1/2 Gliomas

Recurrent Glioma | Low-grade Glioma | Glioma, Malignant | IDH2 Gene Mutation | IDH1 Mutation

United States
Alice Mims
National Cancer Institute (NCI)

Recruiting

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

Acute Myeloid Leukemia

United States

Search clinical trials for: IDH

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations